Lurbinectedin Patent Expiration

Lurbinectedin is Used for treating small cell lung cancer in adult patients who have progressed on or after platinum-based chemotherapy. It was first introduced by Jazz Pharmaceuticals Ireland Ltd in its drug Zepzelca on Jun 15, 2020.

Lurbinectedin Patents

Given below is the list of patents protecting Lurbinectedin, along with the drug name that holds that patent and the company name owning that drug.

Drug Used in Drug Patent Number Drug Patent Title Drug Patent Expiry Drug Owner
Zepzelca US7763615 Ecteinascidin analogs for use as antitumour agents Dec 13, 2029 Jazz

Coming Soon

Patent Strength Analyzer

Will this be useful for you?


Thank you for your response 🥳